News AB Science

Stocks

AB

FR0010557264

Pharmaceuticals

Real-time Euronext Paris Other stock markets 11:58:19 09/07/2026 +04			5-day change	1st Jan Change
0.7510 ^EUR	+1.49%		-2.09%	-51.11%

07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI

All News

Mentions Relevance

07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-01	AB Science, successful private placement
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib
06-17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
06-17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
06-10	AB Science presents new data on Masitinib
06-09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
06-02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
05-26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
05-25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL
05-18	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science : Annual financial results as of 31 December, 2025	PU
05-13	AB Science reports its revenues for the year 2025 and provides an update on its activities	GL
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-04	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	AB Science announces successful capital increase
04-29	AB Science announces the successful completion of a EUR 3.2 million private placement	GL